SPECIALTY INJECTABLE MARKET ANALYSIS

Specialty Injectable Market, By Drug Type (Small Molecule Drugs and Biologics), By Application (Oncology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

On May 15, 2024, Apotex Corp., a pharmaceutical company, announced the launch of Cetrorelix Acetate for Injection 0.25 mg, a generic alternative to Cetrotide in the U.S. This synthetic decapeptide acts as a gonadotropin-releasing hormone (GnRH) antagonist, indicated for preventing premature LH surges in women undergoing controlled ovarian stimulation.
On April 11, 2024, Baxter, a global healthcare company, announced the expansion of its pharmaceuticals portfolio with the launch of five new injectable products in the U.S.
On January 4, 2024, Amneal Pharmaceuticals, Inc., a biopharmaceutical company, launched a total of 39 new retail and injectable medicines in 2023, an increase from 26 new launches in 2022
In December 2023, ITAAN Pharma, a company specializing in sterile injectable manufacturing, announced a collaboration with ACIC Pharmaceuticals, a biopharmaceutical firm, aimed at enhancing product development for a range of injectable product